



Translate! 2021

Metrics and Milestones of Success
25–26 January | Berlin, Germany

BIH Berlin Institute
of Health
Charité & MDC

Online Event

Science
Translational
Medicine
Berlin

DFG

CHARITÉ

PROGRAM

25 Jan 2021 | 1st Day

5:00 pm **Welcome**

GEORG DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

ORLA SMITH | SCIENCE TRANSLATIONAL MEDICINE

[Washington DC Time 11:05 am](#)

5:05 pm **Opening Statements**

AXEL RADLACH PRIES | DEAN, CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

CHRISTOPHER BAUM | CEO, BERLIN INSTITUTE OF HEALTH (BIH)

5:10 pm **Steering vs. Freedom of Translation – Lessons Learned**

MODERATOR: **GEORG DUDA** | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

Co-MODERATOR: **C CZAJKA** | SCIENCE TRANSLATIONAL MEDICINE

Are translational research hubs allowed to pursue their translational opportunities freely? What does this control matrix look like? If de-risking occurs, what risks are considered moving from bench to bedside? What is the culture of project prioritization and selection? How are pet projects and politics avoided? Listen to experiences from large translational science oriented institutions

Angelika Fretzen | Wyss Institute at Harvard University

How To Gate Translational Progress?

[Massachusetts Time 11:15 am](#)

Robert Guldberg | University of Oregon

Building a Culture that Promotes and Accelerates Translation

[Oregon Time 8:20 am](#)

Louise Jones | Medical Research Council

Assessing Translational Progress within Peer Review Processes

[London Time 4:25 pm](#)

Hildegard Büning | Hannover Medical School (MHH)

How Can Translational Research be Empowered?

[Berlin Time 5:30 pm](#)

5:35 – 6:00 pm **Discussion**



Translate! 2021

Metrics and Milestones of Success

25–26 January | Berlin, Germany

BIH Berlin Institute of Health
Charité & MDC

Online Event

Science Translational Medicine

DFG

CHARITÉ

6:00 pm Data Science and Stewardship

MODERATOR: **CAITLIN CZAJKA** | SCIENCE TRANSLATIONAL MEDICINE

[Washington DC Time 12:00 pm](#)

Co-MODERATOR: G DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

Society is now being tapped to provide new real-world data, often in real time. Massive collections of personalized health data by wearables are increasing. But, who vets the quality of data collected en masse? How are such vast datasets collected, curated, and managed in the cloud? How will all of this be verified and protected to be used appropriately and remain traceable? Many published preclinical and clinical studies lack reproducibility and consistency in their messaging. How does the biomedical research enterprise enhance credibility and data veracity in both fundamental and translational forums? Experts will describe the current issues, policies and procedures with stewarding massive medical data sets and better reproducing biomedical studies to improve reliability.

Jennifer Goldsack | Digital Medicine Society (DiME)

Data Governance and Privacy in the Age of Digital Medicine

[Massachusetts Time 12:05 pm](#)

Christof von Kalle | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin
Translation by Data Sciences – Cancer as a Role Model?

How To Boost

[Berlin Time 6:10 pm](#)

Christine Manta | Elektra Labs

Digital Medicine, Biomarkers, Diagnostics, and Therapeutics

[California Time 9:15 am](#)

Andrew Morris | The University of Edinburgh

Maintaining the Integrity of a Trustworthy Health Data Ecosystem

[Edinburgh Time 5:20 pm](#)

6:25 – 6:50 pm Discussion

6:50 – 6:55 pm Break

6:55 pm How to Judge Translational Progress and Performance

MODERATOR: **ORLA SMITH** | SCIENCE TRANSLATIONAL MEDICINE

[Washington DC Time 12:55 pm](#)

Co-MODERATOR: J SCHULZ | RWTH AACHEN

Common metrics used to assess real world translational success include impact factors, publications and patents for academics, and product launch, marketing and publicity for industry. Many national funding incentives use performance leveraged budgeting (e.g., impact factors or publication production based research awards). Synergies between basic and translational science are often advocated as essential, but how much rote discovery/serendipity “blue-sky” fundamental research is proper? How much risk is allocated to translational-oriented research? How are real world translational research efforts ranked and assessed to ensure high quality global translational sciences? Are Translational Readiness Levels a solution? What benchmarks for success are appropriate?

Hans-Dieter Volk | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Translational Readiness Levels – A Feasible Strategy to Judge on Progress?

[Berlin Time 7:00 pm](#)

Hans-Gustaf Ljunggren | Karolinska Institute

The Value of Creating Well-Organized Biobanks for Translational Research: The Karolinska COVID-19 Case

[Sweden Time 7:05 pm](#)

Jeffrey Bluestone | The University of California, San Francisco (UCSF)

Challenges of Rewarding Entrepreneurship in Translational Academic Research

[California Time 10:10 am](#)



Translate! 2021

Metrics and Milestones of Success
25–26 January | Berlin, Germany

BIH Berlin Institute
of Health
Charité & MDC

Online Event

Science
Translational
Medicine
Berlin

DFG

CHARITÉ

7:15 – 7:40 pm

Discussion

7:40 – 7:50 pm

Break

7:50 – 8:10 pm

Report on Consensus Process I

Measuring Translation – What Works, What Does Not?

Contribute to a conference consensus statement to guidance on metrics that better inform translational progress and rank success.

Glenn Prestwich | Washington State University
[Washington State Time 10:50 am](#)

Hans-Dieter Volk | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Brenna Rauw | 12Bridge LLC, Portland
[Portland Time 10:50 am](#)

8:10 – 8:30 pm

Report on Consensus Process II

The Role of Data Reproducibility in Translation

Contribute to a conference consensus statement on improving biomedical data stewardship, veracity, validation and confidence, and how this might be enforced to improve translational efficiency.

Ronenn Roubenoff | Novartis Institutes for Biomedical Research
[Switzerland Time 8:10 pm](#)

Ulrich Dirnagl | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Petra Reinke | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

8:30 – 8:35 pm

Break

8:35 pm

**Digital Labs: A Unique Translation Engine
for Digital Health in Research Hospitals**

KLAUS NITSCHKE | BERLIN INSTITUTE OF HEALTH (BIH)

8:50 pm

Challenge@Translate!

GEORG DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

End of First Day



Translate! 2021

Metrics and Milestones of Success

25–26 January | Berlin, Germany

BIH Berlin Institute
of Health
Charité & MDC

Online Event

Science
Translational
Medicine
Berlin

DFG

CHARITÉ

26 Jan 2021 | 2nd Day

5:00 pm

Warm up & Summary of First Day

DAVID GRAINGER | UNIVERSITY OF UTAH

[Utah Time 9:00 am](#)

5:05 – 5:40 pm

**RADx – Unexpected Opportunity Under Unexpected Circumstances
With Unexpected Consequences**

BRUCE J. TROMBERG | NATIONAL INSTITUTES OF HEALTH (NIH)

[Maryland Time 11:05 am](#)

5:40 pm

**Regulatory Sciences for Novel Therapies – From Cells,
Devices and Apps**

MODERATOR: **DAVID GRAINGER** | UNIVERSITY OF UTAH

[Utah Time 9:40 am](#)

Co-MODERATOR: *O SMITH* | SCIENCE TRANSLATIONAL MEDICINE

Regulatory agencies can enforce new regulations in unpredictable ways, creating risks in translation. Globalization of regulatory policy is inconsistent and defaults to country-specific enforcement. Regulatory sciences are now being developed to produce quantitative research specific to regulatory requirements. Other developments (adaptive clinical trial designs, digital twins, Nobel Prizes) are changing translational perspectives and approval opportunities.

Experts present models, metrics and experiences for translating biomedical products in different global environments.

Setsuko Hashimoto | CellSeed Inc.

Accelerating Translational Research in Advanced Technologies

[Tokyo Time 1:45 am \(Morning of 27 Jan\)](#)

Andrew Carr | University of Oxford

New Approaches to Value-Driven Device Developments

[Oxford UK Time 4:50 pm](#)

Stefan Schreck | DG SANTE C European Commission

From Creating New Knowledge To Its Application: A New Approach at EU Level

[Luxemburg Time 5:55 pm](#)

Caroline Paunov | Organization for Economic Co-Operation and Development (OECD)

Inclusive Innovation in the Digital Age and University-Industry Collaboration in Innovation

[France Time 6:00 pm](#)

6:05 – 6:25 pm

Discussion

6:25 – 6:30 pm

Break



Translate! 2021

Metrics and Milestones of Success

25–26 January | Berlin, Germany

BIH Berlin Institute of Health
Charité & MDC

Online Event

Science Translational Medicine

DFG

CHARITÉ

6:30 pm

Translational Hubs – Infrastructures to Boost Translation

MODERATOR: **JÖRG SCHULZ** | RWTH AACHEN (IZKF)

Co-MODERATOR: **HD VOLK** | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

Academic cultures and structures are seen to both limit and boost translation – often steering innovation from the bottom up through a labyrinth of barriers inconsistent with translation. New translationally oriented institutes are now acting independently of their academic hosts (e.g. Zuckerberg/Stanford; Gladstones/PICU/UCSF) whereas others are enabled by their institutional directives (e.g. Mayo Clinics, Scripps Institutes). How much entrepreneurial excellence, innovation and translation can be expected in modern academic settings? Can they evolve?

Susanne Herold | University Hospital of Gießen and Marburg (UKGM)

Translation in Times of COVID-19 – and Beyond

[Giessen Time 6:35 pm](#)

Andre Terzic | Mayo Clinic

Practice-Centric Translation Strategy

[Minnesota Time 11:40 am](#)

Stephen Kern | Bill and Melinda Gates Foundation

Essential Characteristics for Effective Translational Research

[West Coast Time 9:45 am](#)

Wolfgang Wick | Heidelberg University Hospital

Neurooncology – Translating Novel Concepts Into Clinical Application

[Heidelberg Time 6:50 pm](#)

6:55 – 7:20 pm

Discussion

7:20 – 7:25 pm

Break

7:25 pm

Accelerated Translation in Times of Global Crises

MODERATOR: **HANS-DIETER VOLK** | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

Co-MODERATOR: **G DUDA** | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN

Many global regulatory agencies have recently developed fast-track approval processes in response to clinical needs, commercial demands, and researcher inputs. Can this same strategy be further adapted for more general approaches to biomedical translation?

Zami Aberman | Pluristem Therapeutics Inc.

Allogeneic “Living Drugs” Treatments: Translation From Acute (Muscle) Injury and Chronic Ischemia to Treatment of Acute Respiratory Distress Syndrome (ARDS) Resulting From COVID-19.

[Israel Time 8:30 pm](#)

Peter Marks | U. S. Food and Drug Administration (FDA)

Accelerated Product Development and Approval

[Maryland Time 1:35 pm](#)

Katja Brose | Chan Zuckerberg Initiative

A Basic Science Perspective on Translational Challenges in Times of Global Challenges

[California Time 10:40 am](#)

Klaus Cichutek | Paul-Ehrlich-Institute (PEI)

Accelerated Approval Process in Times of Crises

[Langen Time 7:45 pm](#)



Translate! 2021

Metrics and Milestones of Success

25–26 January | Berlin, Germany

BIH Berlin Institute
of Health
Charité & MDC

Online Event

Science
Translational
Medicine
Berlin

DFG

CHARITÉ

7:50 – 8:10 pm

Discussion

8:10 – 8:15 pm

Break

8:15 pm

Discussion on Consensus Paper Draft I

Measuring Translation – What Works, What Does Not?

Refine the conference consensus statement for guidance on metrics that better inform translational progress and rank success.

Glenn Prestwich | Washington State University

[Washington State Time 11:15 am](#)

Hans-Dieter Volk | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Brenna Rauw | 12Bridge LLC

[Portland Time 11:15 am](#)

8:35 pm

Discussion on Consensus Paper Draft II

The Role of Data Reproducibility in Translation

Refine the conference consensus statement on improving biomedical data stewardship, veracity, validation and confidence, and how this might be enforced to improve translational efficiency.

Ronenn Roubenoff | Novartis Institutes for Biomedical Research

[Switzerland Time 8:35 pm](#)

Ulrich Dirnagl | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

Petra Reinke | Berlin Institute of Health (BIH) | Charité – Universitätsmedizin Berlin

8:55 pm

Closing Remarks and

Announcement of Winning Pitch

CAITLIN CZAJKA | SCIENCE TRANSLATIONAL MEDICINE

[Washington DC Time 2:55 pm](#)

GEORG DUDA | BERLIN INSTITUTE OF HEALTH (BIH) | CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN